Published in J Biol Chem on July 25, 1990
Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest (2006) 3.51
Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands. J Virol (2000) 2.04
Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood (2011) 1.82
Renal inflammation: targeted iron oxide nanoparticles for molecular MR imaging in mice. Radiology (2010) 1.75
Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med (2006) 1.57
Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1. J Exp Med (1992) 1.46
Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes. J Exp Med (1993) 1.44
Characterization of the echovirus 7 receptor: domains of CD55 critical for virus binding. J Virol (1995) 1.34
A role for the epidermal growth factor-like domain of P-selectin in ligand recognition and cell adhesion. J Cell Biol (1994) 1.27
Mapping of the C3b-binding site of CR1 and construction of a (CR1)2-F(ab')2 chimeric complement inhibitor. J Exp Med (1991) 1.18
Infection of human thymocytes by Epstein-Barr virus. J Exp Med (1991) 1.15
Characterization of an Epstein-Barr virus receptor on human epithelial cells. J Exp Med (1992) 1.12
The crystal structure of human CD21: Implications for Epstein-Barr virus and C3d binding. Proc Natl Acad Sci U S A (2002) 1.11
Epstein Barr virus/complement C3d receptor is an interferon alpha receptor. EMBO J (1991) 1.06
Mutational analysis of the cellular receptor for poliovirus. J Virol (1991) 1.04
Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats. J Virol (1991) 1.01
Laser-capture microdissection of oropharyngeal epithelium indicates restriction of Epstein-Barr virus receptor/CD21 mRNA to tonsil epithelial cells. J Oral Pathol Med (2008) 1.00
Epstein-Barr virus infection of human astrocyte cell lines. J Virol (1999) 0.91
Determination of soluble CD21 as a parameter of B cell activation. Clin Exp Immunol (1993) 0.89
N glycosylation of the virus binding domain is not essential for function of the human poliovirus receptor. J Virol (1992) 0.85
CD46 short consensus repeats III and IV enhance measles virus binding but impair soluble hemagglutinin binding. J Virol (1997) 0.85
Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis. J Biol Chem (2009) 0.83
Determination of the role for CD21 during Epstein-Barr virus infection of B-lymphoblastoid cells. J Virol (1994) 0.83
Human complement receptor 2 (CR2/CD21) as a receptor for DNA: implications for its roles in the immune response and the pathogenesis of systemic lupus erythematosus (SLE). Mol Immunol (2012) 0.81
Biophysical investigations of complement receptor 2 (CD21 and CR2)-ligand interactions reveal amino acid contacts unique to each receptor-ligand pair. J Biol Chem (2010) 0.78
The Epstein-Barr virus-binding site on CD21 is involved in CD23 binding and interleukin-4-induced IgE and IgG4 production by human B cells. Immunology (1996) 0.75
Co-operation between human CR1 (CD35) and CR2 (CD21) in internalization of their C3b and iC3b ligands by murine-transfected fibroblasts. Immunology (1999) 0.75
Antiphospholipid syndrome patients display reduced titers of soluble CD21 in their sera irrespective of circulating anti-beta2-glycoprotein-I autoantibodies. Rheumatol Int (2008) 0.75
A critical role for murine complement regulator crry in fetomaternal tolerance. Science (2000) 3.27
Genetic and linguistic differentiation in the Americas. Proc Natl Acad Sci U S A (1993) 2.85
Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc Natl Acad Sci U S A (1996) 2.71
The regulators of complement activation (RCA) gene cluster. Adv Immunol (1989) 2.63
Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc Natl Acad Sci U S A (1987) 2.62
Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann Rheum Dis (2007) 2.38
Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J Immunol (1998) 1.96
C3bi-binding protein on Candida albicans: temperature-dependent expression and relationship to human complement receptor type 3. Infect Immun (1989) 1.76
Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity. J Exp Med (1987) 1.74
Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J Exp Med (1995) 1.74
Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol (2000) 1.55
Mouse Crry/p65. Characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF. J Immunol (1993) 1.50
Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1. J Exp Med (1992) 1.46
Genomic organization and polymorphisms of the human C3d/Epstein-Barr virus receptor. J Biol Chem (1989) 1.43
Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum (2004) 1.43
Structure of complement receptor 2 in complex with its C3d ligand. Science (2001) 1.40
Mouse complement receptors type 1 (CR1;CD35) and type 2 (CR2;CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. J Immunol (1997) 1.39
Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity (2001) 1.36
Specificity of membrane complement receptor type three (CR3) for beta-glucans. Complement (1987) 1.35
A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2. J Immunol (1990) 1.32
Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J Immunol (1998) 1.32
Dyslipoproteinemia in the course of active rheumatoid arthritis. Semin Arthritis Rheum (1992) 1.31
Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nat Immunol (2001) 1.30
The gene encoding decay-accelerating factor (DAF) is located in the complement-regulatory locus on the long arm of chromosome 1. J Exp Med (1987) 1.29
Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol (2001) 1.24
Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF). J Immunol (1985) 1.23
Complement receptor 3 (CR3, Mac-1, integrin alpha M beta 2, CD11b/CD18) is required for tyrosine phosphorylation of paxillin in adherent and nonadherent neutrophils. J Cell Biol (1994) 1.19
Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides. At least two distinct sites are necessary for ligand-receptor interaction. J Biol Chem (1991) 1.19
Mouse Crry/p65 is a regulator of the alternative pathway of complement activation. Eur J Immunol (1993) 1.18
Identification of a third component of complement-binding glycoprotein of human platelets. J Clin Invest (1986) 1.17
Identification of an alternative polyadenylation site in the human C3b/C4b receptor (complement receptor type 1) transcriptional unit and prediction of a secreted form of complement receptor type 1. J Exp Med (1988) 1.16
Human peripheral blood monocytes display surface antigens recognized by monoclonal antinuclear antibodies. J Clin Invest (1985) 1.15
Complement inhibitor, complement receptor 1-related gene/protein y-Ig attenuates intestinal damage after the onset of mesenteric ischemia/reperfusion injury in mice. J Immunol (2001) 1.14
Normal polymorphic variations and transcription of the decay accelerating factor gene in paroxysmal nocturnal hemoglobinuria cells. Proc Natl Acad Sci U S A (1988) 1.14
Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis (2002) 1.13
Analysis of epitope expression and the functional repertoire of recombinant complement receptor 2 (CR2/CD21) in mouse and human cells. J Immunol (1989) 1.12
Transgenic mice overexpressing the complement inhibitor crry as a soluble protein are protected from antibody-induced glomerular injury. J Exp Med (1998) 1.08
Human complement C3b/C4b receptor (CR1) mRNA polymorphism that correlates with the CR1 allelic molecular weight polymorphism. Proc Natl Acad Sci U S A (1987) 1.08
Identification of new SLE-associated genes with a two-step Bayesian study design. Genes Immun (2009) 1.07
Epithelial secretion of C3 promotes colonization of the upper urinary tract by Escherichia coli. Nat Med (2001) 1.06
Analysis of the human regulators of complement activation (RCA) gene cluster with yeast artificial chromosomes (YACs). Genomics (1992) 1.06
gp140, a C3b-binding membrane component of lymphocytes, is the B cell C3dg/C3d receptor (CR2) and is distinct from the neutrophil C3dg receptor (CR4). Eur J Immunol (1985) 1.05
Moesin, and not the murine functional homologue (Crry/p65) of human membrane cofactor protein (CD46), is involved in the entry of measles virus (strain Edmonston) into susceptible murine cell lines. J Gen Virol (1995) 1.04
An intronic silencer regulates B lymphocyte cell- and stage-specific expression of the human complement receptor type 2 (CR2, CD21) gene. J Immunol (1998) 1.03
CD23 interacts with a new functional extracytoplasmic domain involving N-linked oligosaccharides on CD21. J Immunol (1994) 1.03
Cholesterol crystals in synovial and bursal fluid. Semin Arthritis Rheum (1993) 1.02
Increased expression of activation-induced cytidine deaminase is associated with anti-CCP and rheumatoid factor in rheumatoid arthritis. Scand J Immunol (2009) 1.02
Structural gene for human membrane cofactor protein (MCP) of complement maps to within 100 kb of the 3' end of the C3b/C4b receptor gene. J Exp Med (1989) 1.01
Structural and functional studies on the human C3b/C4b receptor (CR1) purified by affinity chromatography using a monoclonal antibody. Complement (1986) 1.01
The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG (2010) 1.01
Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg. Biochemistry (2001) 1.00
Cigarette smoking, disease severity and autoantibody expression in African Americans with recent-onset rheumatoid arthritis. Ann Rheum Dis (2008) 0.99
Crry and CD59 regulate complement in rat glomerular epithelial cells and are inhibited by the nephritogenic antibody of passive Heymann nephritis. J Immunol (1995) 0.98
Cell surface proteins reacting with activated complement components. Complement Inflamm (1989) 0.98
Complement activation pathways in murine immune complex-induced arthritis and in C3a and C5a generation in vitro. Clin Exp Immunol (2009) 0.97
Resting B cells from New Zealand Black mice demonstrate a defect in apoptosis induction following surface IgM ligation. J Immunol (1996) 0.96
The polymorphism of the C3b/C4b receptor in the normal population and in patients with systemic lupus erythematosus. Clin Exp Immunol (1987) 0.96
Identification and characterization of a novel membrane activation antigen with wide cellular distribution. Eur J Immunol (1988) 0.96
Enhancement of protein S anticoagulant function by beta2-glycoprotein I, a major target antigen of antiphospholipid antibodies: beta2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein. Thromb Haemost (1999) 0.95
Inhibiting the complement system does not reduce injury in renal ischemia reperfusion. J Am Soc Nephrol (2001) 0.95
Analysis of C3b/C3d binding sites and factor I cofactor regions within mouse complement receptors 1 and 2. J Immunol (1994) 0.94
T lymphocyte expression of complement receptor 2 (CR2/CD21): a role in adhesive cell-cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE). Clin Exp Immunol (1992) 0.94
Modulation of mouse endotoxic fever by complement. Infect Immun (2002) 0.93
Complement regulation in the rat glomerulus: Crry and CD59 regulate complement in glomerular mesangial and endothelial cells. Kidney Int (1995) 0.93
Cigarette smoking and the risk of systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis (2006) 0.93
Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus (1998) 0.92
Solution structures of complement components by X-ray and neutron scattering and analytical ultracentrifugation. Biochem Soc Trans (2002) 0.92
Gamma-glutamyl transpeptidase, an ecto-enzyme regulator of intracellular redox potential, is a component of TM4 signal transduction complexes. Eur J Immunol (1998) 0.91
Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells. J Immunol (1998) 0.91
A site in the complement receptor 2 (CR2/CD21) silencer is necessary for lineage specific transcriptional regulation. Int Immunol (2001) 0.91
Regulation of nuclear antigen expression on the cell surface of human monocytes. J Immunol (1992) 0.91
Characterization of a complement receptor 2 (CR2, CD21) ligand binding site for C3. An initial model of ligand interaction with two linked short consensus repeat modules. J Immunol (1995) 0.91
Generation of recombinant human C3dg tetramers for the analysis of CD21 binding and function. J Immunol Methods (2001) 0.91
Neurocognitive deficits and neuroimaging abnormalities are prevalent in children with lupus: clinical and research experiences at a US pediatric institution. Lupus (2009) 0.91
Structural and functional analysis of CR2/EBV receptor by means of monoclonal antibodies and limited tryptic digestion. Immunology (1988) 0.90
Co-ligation of mouse complement receptors 1 and 2 with surface IgM rescues splenic B cells and WEHI-231 cells from anti-surface IgM-induced apoptosis. Eur J Immunol (1995) 0.90
Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura. J Thromb Haemost (2013) 0.90
Identification of a spontaneously shed fragment of B cell complement receptor type two (CR2) containing the C3d-binding site. Complement (1987) 0.88
Reduction of cortisol levels after single intra-articular and intramuscular steroid injection. Am J Med (1995) 0.88
Complement is activated in kidney by endotoxin but does not cause the ensuing acute renal failure. Kidney Int (2000) 0.88
CR2/CD21 proximal promoter activity is critically dependent on a cell type-specific repressor. J Immunol (2001) 0.88
Analysis of C3b/C4b receptor (CR1) polymorphic variants by tryptic peptide mapping. Mol Immunol (1986) 0.87
Gamma-glutamyl transpeptidase is up-regulated on memory T lymphocytes. Int Immunol (1999) 0.87
Characterization of the human complement receptor 2 (CR2, CD21) promoter reveals sequences shared with regulatory regions of other developmentally restricted B cell proteins. J Immunol (1991) 0.87
Complement receptors. Curr Opin Immunol (1992) 0.86
The ectoenzyme gamma-glutamyl transpeptidase regulates antiproliferative effects of S-nitrosoglutathione on human T and B lymphocytes. J Immunol (1999) 0.86
Expression of human complement receptor 2 (CR2, CD21) in Cr2-/- mice restores humoral immune function. J Immunol (2000) 0.86
Lymphocyte subpopulation alterations induced by intravenous megadose pulse methylprednisolone. J Rheumatol (1984) 0.86
CD21 augments antigen presentation in immune individuals. Eur J Immunol (1997) 0.86
Expression and function of membrane regulators of complement on rat astrocytes in culture. Immunology (1996) 0.86
Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor. Immunology (1988) 0.85
Complement component c5a is integral to the febrile response of mice to lipopolysaccharide. Neuroimmunomodulation (2005) 0.85
Complement opsonization is required for presentation of immune complexes by resting peripheral blood B cells. J Immunol (1998) 0.85
Characterization of C3-binding proteins on mouse neutrophils and platelets. J Immunol (1997) 0.84
Supervised machine learning and logistic regression identifies novel epistatic risk factors with PTPN22 for rheumatoid arthritis. Genes Immun (2010) 0.83
Macrophage-colony-stimulating factor regulates expression of the integrins alpha 4 beta 1 and alpha 5 beta 1 by murine bone marrow macrophages. Proc Natl Acad Sci U S A (1995) 0.83